Partnership to Deliver Sterile Connector and Fill
Technology
Provides Quicker Set-Up, Greater Flexibility,
Lower Costs and Faster Access to Medicines
ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in
single-use bioprocess solutions, announced today it has invested in
sterile connector and sterile fill technology developed by Medical
Instill Technologies (Medinstill), a company dedicated to
developing solutions for the transfer and packaging of high purity
fluids at unmatched safety levels.
The investments focus on the INTACTâ„¢ family of products
developed by Medinstill. These innovative technologies will be
deployed in sterile filling, sterile multiple-dose dispensing,
sterile transfer, and packaging sterilization solutions that
address current critical issues in the pharmaceutical, biotech, and
healthcare industries.
"ATMI has a strong history of internal innovation as well as
collaboration with other innovators," said Chief Executive Office
of ATMI, Doug Neugold. "Collaboration with Medinstill is another
great example of this strategy. Through this investment, we will
develop a suite of products that address critical issues from our
customers' perspective as they continue to adopt single-use
technology and other new inventions. "Our customers are looking for
ways to reduce cost, minimize time to market and increase
manufacturing flexibility. The INTACT solutions that we are
developing with Medinstill enable efficiencies that will help us
help them realize their objectives."
"We are happy to partner with a company of ATMI's stature,"
added Daniel Py, MD, Sc.D., Chairman of Medinstill. "With its
global reach and history of technical innovation in
biopharmaceutical manufacturing, I believe ATMI can be instrumental
in allowing us to bring products with the highest safety levels to
those in need. The INTACT technology provides a means to rapidly
reduce drug shortages while overcoming the difficulties associated
with installing and running aseptic lines in emerging markets, such
as access to specially trained personnel, all at a fraction of the
cost of traditional aseptic filling lines. The synergy between our
INTACT Closed Transfer Systems and disposable technologies from
ATMI allows us together to quickly install turn-key fill finish
lines, bringing many benefits to a large number of manufacturers.
We look forward to a long and successful relationship with
ATMI."
INTACT Filler technology allows for sterile fill of multiple
products into a broad range of containers and dosing devices in
conditions significantly less stringent and less expensive than
clean rooms, providing an avenue for meeting demand in domestic and
international locations. ATMI and Medinstill have formed a joint
venture to market and manufacture this technology for the
biopharmaceutical industry. The technology is scalable from small
lots in benchtop systems to industrial scales that enable the
global biopharmaceutical and vaccine markets.
INTACT Connector technology will allow for sterile re-use of
disposable connectors. ATMI has exclusively licensed this
technology for the biopharmaceutical industry and will directly
commercialize the connector products once development activity is
completed. The INTACT connector technology will be the only
multiple-use sterile connector, which guarantees no contact between
the liquid path and the external environment and ensures no ingress
of air, bacteria, yeasts or mold. The INTACT Sterile connector
technology is a major breakthrough for situations requiring
transfers of fluids under sterile conditions without a controlled
environment for the pharmaceutical and bioprocessing
industries.
About ATMI
ATMI, Inc. provides specialty semiconductor materials, and safe,
high-purity materials handling and delivery technologies designed
to increase process efficiencies for the global semiconductor, flat
panel, and life sciences industries. For more information, please
visit http://www.atmi.com.
About ATMI LifeSciences
ATMI LifeSciences is an acknowledged technology leader in the
field of single-use bioprocess systems and consumables for the
pharmaceutical and biopharmaceutical industries. Its innovative,
market-leading portfolio of custom-engineered, flexible packaging
solutions, single-use storage systems, mixers and bioreactors is
driving bioprocess efficiency and delivering value for
biopharmaceutical companies around the world. For more information,
please visit www.atmi-lifesciences.com.
About Medinstill
Medical-Instill Technologies is a company dedicated to the
invention, development and commercialization of technologies for
the contamination free manufacturing and delivery of
pharmaceutical, cosmetic and nutrition products. Medinstill holds
over 100 patents for the contamination free filling and multiple
dose delivery for non-preserved products. In addition, Medinstill's
devices are conceived for enhancing drug efficacy and reducing side
effects through accurate, consumer friendly, metered dose delivery
systems for topical applications on skin and mucous membranes.
Medinstill continues to pursue partnerships and licenses for the
commercialization of their filling technology and delivery devices
in specific fields.
ATMI and the ATMI logo are trademarks, or registered trademarks,
of Advanced Technology Materials, Inc., in the United States, other
countries or both.
MEDINSTILL and INTACT are trademarks of Medical Instill
Technologies, Inc. and are Reg. U.S. Pat. & Tm. Off. and in
other countries.
Forward Looking Statements
Statements contained herein that relate to ATMI's future
performance, including, without limitation, statements with respect
to ATMI's anticipated results of operations or level of business
for 2013 or any other future period, are forward-looking statements
within the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on current
expectations only and are subject to certain risks, uncertainties,
and assumptions, including, but not limited to, changes in
semiconductor and life sciences industry growth (including, without
limitation, wafer starts) or ATMI's markets; competition, problems,
or delays developing, commercializing, and delivering new products;
customer-driven pricing pressure; potential loss of key customers;
problems or delays in integrating acquired operations and
businesses; uncertainty in the credit and financial markets;
ability to protect ATMI's proprietary technology; and other factors
described in ATMI's Form 10-K for the year ended December 31, 2012
and other subsequent filings with the Securities and Exchange
Commission. Such risks and uncertainties may cause actual results
to differ materially from those expressed in our forward-looking
statements. ATMI undertakes no obligation to update any
forward-looking statements.
CONTACT: ATMI Contact:
Troy Dewar
Director of Investor Relations and Corporate Communications
203.207.9349
tdewar@atmi.com
Media Contact:
Beth Willers
Impress Labs
415.846.9891
beth@impresslabs.com
Atmi Inc. (MM) (NASDAQ:ATMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atmi Inc. (MM) (NASDAQ:ATMI)
Historical Stock Chart
From Jul 2023 to Jul 2024